Transfusion Therapy in Children With Sickle Cell Disease.

Adlette Inati, Anthony G Mansour, Toni Sabbouh, Ghid Amhez, Ahmad Hachem, Hussein A Abbas

Journal: Journal of pediatric hematology/oncology 2017;39(2):126-132

PMID: 27509379

Abstract

Hydroxyurea, blood transfusions, and hematopoietic stem cell transplantation represent the 3 disease-modifying therapies in children with sickle cell disease (SCD). Blood transfusions play an increasingly important role in both prevention and management of SCD complications in this age group. This review will focus on the indications of blood transfusion in children with SCD and modalities of its administration. It will also highlight the complications of this life-saving therapy and ways of optimizing transfusion to minimize its associated risks.

Address: *Department of Pediatrics, Lebanese American University and University Medical Center Rizk Hospital, Beirut †School of Medicine, Lebanese American University, Byblos, Lebanon ‡Department of Molecular and Cellular Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX.

DOI: 10.1097/MPH.0000000000000645

Link outs

Free resources

Medical:

https://medlineplus.gov/sicklecelldisease.html

Other Literature Sources:

https://scite.ai/reports/27509379

Subscription / membership required

Full Text Sources:

MeSH Terms: Anemia, Sickle Cell, Blood Group Incompatibility, Blood Transfusion, Blood Viscosity, Blood-Borne Pathogens, Combined Modality Therapy, Exchange Transfusion, Whole Blood, Forecasting, Humans, Iron Chelating Agents, Iron Overload, Multiple Organ Failure, Splenectomy, Stroke, Transfusion Reaction